Use of Meropenem in a Tertiary Pediatric Hospital in Costa Rica and Its Role in the Era of Antimicrobial Stewardship.
antibiotic resistance
antimicrobial stewardship
meropenem
pediatrics
therapeutics
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
accepted:
21
06
2021
entrez:
26
7
2021
pubmed:
27
7
2021
medline:
27
7
2021
Statut:
epublish
Résumé
Background Understanding antibiotic profiles and their resistance patterns can improve hospital quality care and optimize clinical outcomes. This paper characterizes the use of meropenem in the National Children's Hospital of Caja Costarricense del Seguro Social (CCSS) in Costa Rica, and its role in antibiotic stewardship. Methods This is a retrospective observational study from hospitalized patients under 13 years of age that received meropenem as part of their treatment. Patients were identified through medical and pharmacy records. Data was summarized using frequencies and percentages for categorical variables, means and standard deviations for normally distributed continuous variables, and medians with interquartile ranges (IQR) for non-normally distributed continuous variables. Results A total of 181 of the 309 selected patients met inclusion criteria. Median age was 21 months (IQR: 4.0-79.0). Mean length of stay was 31 days (16.0-58.0). The most frequent diagnosis was septic shock (29%). 87% of patients received at least one antibiotic prior to receiving meropenem; 71% of patients received a second antibiotic simultaneously with meropenem. In 113 (62%) cases, meropenem was prescribed as empirical therapy. The most frequent isolate was extended-spectrum ß-lactamase
Identifiants
pubmed: 34306876
doi: 10.7759/cureus.15809
pmc: PMC8294019
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e15809Informations de copyright
Copyright © 2021, Chacón-González et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Gut Microbes. 2016 Sep 2;7(5):443-9
pubmed: 27472377
Drugs. 2008;68(6):803-38
pubmed: 18416587
Nat Chem Biol. 2015 Nov;11(11):855-61
pubmed: 26368589
J Chemother. 1998 Apr;10(2):108-13
pubmed: 9603635
J Pediatric Infect Dis Soc. 2015 Dec;4(4):e127-35
pubmed: 26582880
Pediatr Infect Dis J. 2015 Nov;34(11):1203-6
pubmed: 26301498
Nat Microbiol. 2016 Mar 07;1:16024
pubmed: 27572443
J Infect Chemother. 2016 Jan;22(1):1-13
pubmed: 26620376
Clin Infect Dis. 2017 Feb 1;64(3):257-264
pubmed: 28013264
BMC Pediatr. 2018 Jun 27;18(1):208
pubmed: 29950162
Clin Pediatr (Phila). 2019 Oct;58(11-12):1291-1301
pubmed: 31179745
J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):219-226
pubmed: 27021036
Pediatr Infect Dis J. 2017 Apr;36(4):358-363
pubmed: 27918382
Ther Drug Monit. 2003 Oct;25(5):593-9
pubmed: 14508383
Pediatrics. 2015 Jan;135(1):33-9
pubmed: 25489018
Enferm Infecc Microbiol Clin. 2014 Dec;32(10):647-53
pubmed: 24355607
Eur J Clin Microbiol Infect Dis. 2018 Jul;37(7):1211-1220
pubmed: 29644540
Antimicrob Resist Infect Control. 2020 Jan 3;9(1):3
pubmed: 31911831
Front Pediatr. 2018 Oct 12;6:294
pubmed: 30370263
Infection. 2017 Aug;45(4):493-504
pubmed: 28397171
Int J Antimicrob Agents. 2016 Aug;48(2):151-7
pubmed: 27345269
Clin Infect Dis. 2012 Dec;55(11):1495-502
pubmed: 22955430
J Antimicrob Chemother. 2018 Mar 1;73(3):569-580
pubmed: 29182785